Project Grant R43AG097351
Award Date 9/22/25
Completion Date 3/22/26
Dollars Obligated $577K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Rocky River, OH 44116, USA
Similar Awards
- This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $500,000.00 to Alzarrok Bio LLC to develop a peptide-based multi-target drug for Alzheimer's disease (AD). The goal is to demonstrate the in vivo efficacy of the drug candidate, ALZ100, in inhibiting neuroinflammation and neurodegeneration in an AD mouse model. The project will first determine the therapeutic concentration of ALZ100 in the brain and then evaluate its effects on key...
- This federal Project Grant award of $3,297,926 from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research to develop novel biomaterials that can prevent, halt, and potentially cure Alzheimer's disease (AD). The research aims to design and evaluate peptide hybrid biomaterials that can stabilize the helical conformation of amyloid-beta (Aβ) peptides, thereby shifting the equilibrium of Aβ aggregation away from toxic oligomers and fibrils. Key objectives include...
- This Project Grant award of $252,124 from the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866) is focused on drug discovery targeting the amyloid precursor protein transmembrane domain to selectively reduce amyloid production for the treatment of Alzheimer's disease. The 2-year project aims to carry out structure-activity relationship (SAR) analysis and lead optimization of a compound (C1) in Aim 1, and then conduct in vivo pharmacokinetic and...
- This Project Grant award from the National Institute on Aging's (NIA) Aging Research Federal Grant Program (CFDA 93.866) is supporting Advantage Therapeutics, Inc. to conduct IND-enabling studies on a small molecule drug candidate that is disease-modifying for Alzheimer's disease. The goal is to advance this low-cost, long-acting treatment option through preclinical and IND-enabling activities. The $1,249,957 award runs from September 2025 through May 2027 and aims to develop a therapy that...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund the development of a novel Alzheimer's disease therapeutic using targeted nanoparticles. The $504,732 award to Aphios Corp, a minority-owned biotechnology company, will support two phases of research. In Phase I, the company will nanoencapsulate an anti-CCR5 drug in targeted and non-targeted nanoparticles, characterize the formulations, and evaluate their impact on in vitro models of brain...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $994,436.00 to Transchromix LLC to develop novel brain-penetrant drugs for treating Alzheimer's disease (AD). The key products and services being delivered include: Discovering a noncanonical, translation regulatory function of the histone methyltransferase G9A in AD pathogenesis using a chromatin-activity-based chemoproteomic (ChAC) approach to dissect AD heterogeneity. Deducing the mechanism...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $499,883 to Degrome Therapeutics, Inc. to develop small-molecule degraders of the amyloid precursor protein (APP) as novel therapeutics for Alzheimer's disease (AD). The project aims to optimize lead APP degrader compounds to improve their potency, solubility, and blood-brain barrier permeability, with the goal of identifying the most promising candidates for further development and evaluation...
- This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $2,432,649 to Virogenics, Inc., a biotechnology company in San Diego, California, to advance the development of CMS121, an innovative drug candidate for the treatment of Alzheimer's disease (AD). The funding will support two key components: 1) A 13-week toxicology study in rats and dogs to enable longer-term clinical trials of CMS121 in human subjects with mild to moderate AD, and 2) The...
- This $498,709 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports preclinical efficacy testing of an ApoE-targeted antibody therapy for treating Alzheimer's disease (AD). The research project, led by Epoch Biotech, LLC, aims to modulate the interaction between apolipoprotein E (ApoE) and glycosaminoglycans (GAGs) using therapeutic humanized antibodies to challenge the progression of AD. The award period is from Aug 20, 2025 to Aug 19, 2026. The...
- This federal Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $499,441 to Acepre, LLC to develop a novel brain-targeted delivery system for the compound N-acetylcysteine (TN-NAC) as a potential treatment for Alzheimer's disease (AD). The key objectives of this Phase I STTR study are to: 1) evaluate the toxicity and pharmacokinetic properties of TN-NAC in mice, and 2) test the therapeutic efficacy of TN-NAC in a 3xTG-AD mouse model of...